Roche Again Delays $4.3B Spark Buy Amid Regulatory Review
Roche and gene therapy company Spark Therapeutics said Tuesday that they are once again pushing back their $4.3 billion merger, electing to refile with U.S. antitrust regulators to allow more time...To view the full article, register now.
Already a subscriber? Click here to view full article